Cytotoxic T lymphocytes (CTLs) recognize peptides presented by HLA class I molecules on the cell surface. The C terminus of these CTL epitopes is considered to be produced by the proteasome. Here we demonstrate that the cytosolic endopeptidases nardilysin and thimet oligopeptidase (TOP) complemented proteasome activity. Nardilysin and TOP were required, either together or alone, for the generation of a tumor-specific CTL epitope from PRAME, an immunodominant CTL epitope from Epstein-Barr virus protein EBNA3C, and a clinically important epitope from the melanoma protein MART-1. TOP functioned as C-terminal trimming peptidase in antigen processing, and nardilysin contributed to both the C-terminal and N-terminal generation of CTL epitopes. By broadening the antigenic peptide repertoire, nardilysin and TOP strengthen the immune defense against intracellular pathogens and cancer.
A r t i c l e s
The production of short peptides (8-12 amino acids in length) presented by HLA class I molecules, called CTL epitopes when recognized by CD8 + cytotoxic T lymphocytes (CTLs), occurs in the cytosol during the continuous turnover of full-length and misfolded proteins into peptides and eventually free amino acids [1] [2] [3] . This cleavage process is accomplished by the multicatalytic proteasome complex and cytosolic peptidases 1, 3 . Tripeptidyl peptidase II (TPPII) 4 , thimet oligopeptidase (TOP) 5, 6 and aminopeptidases 1, 2 have been linked to protein degradation, but the contribution of other (endo)peptidases has remained elusive. A few degradation products of intermediate length (8) (9) (10) (11) (12) (13) (14) (15) (16) amino acids, on average) escape further cytosolic destruction through translocation via the TAP transporter into the endoplasmic reticulum, where they can be trimmed at the N terminus by the endoplasmic reticulum aminopeptidases ERAP1 and ERAP2 (refs. 1,2,7) and, when they bind properly, assemble with HLA class I heterodimers before being routed to the cell surface. To bind to HLA class I, peptides need to comply with the binding motif of the particular HLA class I molecule through the presence of the proper anchor residues located mostly at the second and C-terminal positions in the peptide.
The absence of C-terminal excision of CTL epitopes in cells in which the proteasome is inhibited [8] [9] [10] , together with lack of detection of C-terminal trimming activity in the cytosol or endoplasmic reticulum, has led to the idea that only the proteasome liberates the C terminus 1, 2 . Cytosolic endopeptidases, however, may also produce peptides with a C terminus fit for binding HLA class I from proteindegradation products lacking such an anchor. Indeed, cells treated with proteasome inhibitors still express substantial quantities of peptideloaded HLA class I molecules [11] [12] [13] [14] [15] . Although these compounds are known to not completely inhibit proteasome activity in cells, this finding suggests the existence of a partially proteasome-independent pathway for the generation of HLA class I ligands. So far only a CTL epitope from the human immunodeficiency virus (HIV) protein negative factor (Nef) has been shown to depend on TPPII (ref. 16) , and a human tumor epitope from the melanoma antigen MAGE-A3 is reported to be produced by insulin-degrading enzyme 17 , but the general importance of TPPII and insulin-degrading enzyme in the generation of CTL epitopes is still unclear 17, 18 . Other peptidases that liberate the C terminus of HLA class I ligands are unknown. To define such peptidases, we delineated the precise generation of a CTL epitope with an unambiguously proteasome-independent C terminus and subsequently assessed peptidases thus identified for their general roles in HLA class I antigen processing.
RESULTS PRAME (190) (191) (192) (193) (194) (195) (196) (197) (198) ) has a proteasome-independent C terminus Cleavage that yields a C-terminal lysine residue is not readily accomplished by proteasomes 19 . Therefore, we searched for a CTL epitope presented by HLA-A3, a human HLA class I molecule that binds peptides with a lysine as C-terminal anchor residue. The nine-residue peptide ELFSYLIEK derived from amino acids 190-198 of the tumorassociated protein PRAME 20 ) was selected by binding prediction and bound with high affinity to HLA-A3 ( Supplementary  Fig. 1 ). Digestion of the 27-residue peptide PRA(182-208) ( Fig. 1a) with purified 20S proteasomes showed no cleavage after the epitope's C-terminal Lys198 or in the region flanking the C terminus. In contrast, its N terminus was liberated by efficient proteasomal cleavage before Glu190. Fragments containing Asp189 at the C terminus and complementary fragments with Glu190 as N terminus constituted >7% of the digested material after 1 h of digestion with proteasomes; digestion with immunoproteasomes or constitutive human 20S proteasomes gave similar results (in three experiments). We transfected the erythroleukemia cell line K562, which naturally expresses PRAME, with HLA-A3 to produce K562-A3 cells. Tandem mass spectrometry identified the sequence ELFSYLIEK ) in peptides eluted from HLA-A3 on the surface of K562-A3 cells ( Supplementary  Fig. 2 ). Also, a CTL clone raised against the PRA(190-198) epitope exogenously loaded onto HLA-A3 efficiently recognized K562-A3 cells and other tumor cell lines expressing PRAME and HLA-A3 in cytotoxicity assays (Fig. 1b) , which confirmed natural presentation of the epitope. That same CTL clone (anti-ELFSYLIEK CTL) also recognized exogenously loaded variants of the epitope ELFSYLIEK extended at the C terminus to 11, 12 or 13 residues (ELFSYLIEKVK, ELFSYLIEKVKR and ELFSYLIEKVKRK), but these peptides, although they had HLA-A3-binding affinity (Supplementary Fig. 1 ), were not naturally presented (Supplementary Fig. 2 ). We used this feature K562-A3   182  183  184  185  186  187  188  189  190  191  192  193  194  195  196  197  198  199  200  201  202  203  204  205  206  207 
of the CTL clone to monitor generation of the epitope ELFSYLIEK and its variants described above in the digestion of longer PRAME peptides. Proteasomal digestion of the 25-residue peptide PRA(190-214) (ELFSYLIEK, located at the N terminus) loaded onto EKR B-lymphoblastoid (HLA-A3 + PRAME − ) cells were not recognized by the CTL clone (Fig. 1c) , which confirmed the proteasome independence of this epitope's C terminus.
Nardilysin produces precursors of PRAME (190) (191) (192) (193) (194) (195) (196) (197) (198) We pursued identification of the peptidase(s) that generated the C terminus of the ELFSYLIEK epitope. First, recognition by the anti-ELFSYLIEK CTL was inhibited when we treated K562-A3 cells with the metallopeptidase inhibitor o-phenanthroline, whereas other inhibitors had no effect (Fig. 2a) . As butabindide, an inhibitor of the serine peptidase TPPII, can be inactivated by serum 4 , we further excluded the potential involvement of TPPII (refs. 16,21) by digestion analysis and RNA-mediated interference (RNAi; Supplementary Fig. 3) . Second, to identify the peptidase, we exposed the internally quenched fluorescent 15-residue substrate ELFSYL(-dab)IEKVKRC(-FL) ; underlining indicates the epitope, (-dab) indicates the quencher dabcyl and (-FL) indicates the fluorescein group) to digestion with cytosolic fractions obtained by anion-exchange chromatography of K562-A3 cell lysates. We identified peptidase activity in fraction 37 that cleaved, in a phenanthroline-sensitive way, between the quencher dabcyl at Lys195 and the fluorescein group at position 202, thereby releasing fluorescence (Fig. 2b) . This fraction contained nardilysin as the only peptidase among five proteins identified by tandem mass spectrometry ( Fig. 2b and Supplementary Fig. 4) . Nardilysin, which has so far not been linked to HLA class I antigen processing, is a cytosolic endopeptidase of the pitrilysin family of zinc metalloproteases and is ubiquitiously expressed 22 (UniGene accession code (expressed sequence tag profile), Hs.584782).
Third, digestion of the 25-residue peptide PRA(190-214) (ELFSY LIEKVKRKKNVLRLCCKKLK) with purified nardilysin resulted in highly efficient production of variants of the epitope extended at the C terminus to 11, 12 or 13 residues by cleavage after Lys200, Arg201 or Lys202 (present for 33.9%, 41.2% and 16.9% of fragments, respectively, after 30 min of digestion; Fig. 2c ), in accordance with the specificity of nardilysin in cleaving before or between two basic residues 23, 24 in substrates of up to ~30 amino acids. Indeed, the anti-ELFSYLIEK CTL efficiently recognized the product of digestion with nardilysin when loaded onto HLA-A3 + EKR cells because of the presence of the ELFSYLIEKVK, ELFSYLIEKVKR and ELFSYLIEKVKRK fragments, whereas the product of proteasomal digestion was not recognized (Fig. 2c) . Fourth, nardilysin was needed to generate this epitope in cells, because small interfering RNA (siRNA)-mediated suppression of nardilysin in K562-A3 cells and HeLa-A3 cells (HeLa (PRAME + ) cervical cancer cells transfected with HLA-A3) resulted in much less recognition of these cells by the anti-ELFSYLIEK CTL (Fig. 2d) . Fig. 7 ). Together these findings indicate that nardilysin is indispensable for the endogenous C-terminal preprocessing of the PRA(190-198) epitope by producing cleavage after Lys200, Arg201 and Lys202 but does not excise precisely at the C terminus (Lys198).
Overexpression of nardilysin in HeLa-A3 cells enhanced recognition by the anti-ELFSYLIEK CTL (Supplementary
TOP liberates the C terminus of PRAME (190) (191) (192) (193) (194) (195) (196) (197) (198) We searched for the peptidase that generates the C terminus of the epitope. Because of their cytosolic location, ubiquitous expression and specificity, the main candidates were TOP, neurolysin and insulin-degrading enzyme. Only the suppression of TOP, a ubiquitous endopeptidase expressed mainly in the cytosol and nucleus, by RNAi resulted in much less recognition of K562-A3 cells by anti-ELFSYLIEK CTL; suppression of the other peptidases in these cells had no effect (Fig. 3a) , which indicated involvement of TOP in the endogenous generation of ELFYSLIEK. Purified TOP efficiently cleaved the nardilysin-dependent 12-and 13-residue precursors PRA(190-201) (ELFSYLIEKVKR) and PRA(190-202) (ELFSYLIEKVKRK) directly after the epitope's C-terminal Lys198. Thus, TOP released three or four C-terminal residues, in accordance with its cleavage preference 25, 26 , thereby efficiently producing the exact nine-residue epitope ( Table 1) . We digested the 12-residue peptide PRA(190-201) with TOP and loaded the digestion product onto HLA-A3 + EKR cells and found this was recognized almost as efficiently as the minimal epitope was, whereas the undigested substrate was not A r t i c l e s recognized at these concentrations (Fig. 3b) . Consistent with TOP's preference for peptides 6-17 amino acids in length 27 , longer peptides were not cleaved by TOP ( Supplementary Fig. 8 and data not shown), which indicated that preprocessing by nardilysin into the 12-and 13-residue peptides was needed to make the epitope precursors susceptible to TOP. We confirmed that prediction by digesting the 25-residue peptide PRA(190-214) with both nardilysin and TOP (together); this resulted in the production of ELFSYLIEK. Accordingly, because of the presence of the epitope, the double-digestion product was recognized more efficiently by the CTL clone than was the product of digestion with nardilysin alone, which contained only the precursors (Supplementary Fig. 8) . Thus, the C terminus of the ELFSYLIEK epitope is released through sequential cleavage by nardilysin and TOP. The N terminus of the ELFSYLIEK epitope was generated by efficient proteasomal cleavage between Asp189 and the N-terminal Glu190 (Fig. 1a) achieved by the caspase-like activity of the proteasome. This cleavage was completely blocked by a specific inhibitor of the caspase-like proteasome activity (AcAlaProNleLeuVSOH) 28 , as shown by digestion of the 27-residue peptide PRA(172-198) ( Supplementary Fig. 9a,b) . As expected, after treatment of cells with this inhibitor, recognition of the cells by the anti-ELFSYLIEK CTL was much lower ( Supplementary  Fig. 9c) ; conversely, the general proteasome inhibitor epoxomicin only partially inhibited cleavage before the N terminus ( Supplementary  Fig. 9a,b) . Notably, after treatment of cells with epoxomicin or other general proteasome inhibitors, the presentation of ELFSYLIEK was much greater (Supplementary Fig. 9c ), probably because of less competition with epoxomicin-sensitive HLA-A3 ligands.
The findings reported above indicated that the proteasome, nardilysin and TOP together produced the minimal epitope in the cytosol (Supplementary Fig. 10a ). As expected, presentation of the epitope was completely dependent on transport into the endoplasmic reticulum by the transporter protein TAP (Supplementary Fig. 11a ). The ELFSYLIEK peptide was efficiently transported by TAP into the endoplasmic reticulum, whereas the 12-and 13-residue epitope precursors were translocated less efficiently (Supplementary Fig. 11b) . Thus, precursors produced by nardilysin are available in the cytosol for processing by TOP, whereas the minimal epitope, after it is produced, can rapidly escape from cytosolic destruction by translocation into the endoplasmic reticulum. This evidence links nardilysin and TOP to the production of CTL epitopes. Do these endopeptidases, either apart or together, have a more general role in HLA class I antigen processing? Nardilysin can generate both N termini and C termini Nardilysin in principle can support the generation of both the C terminus and the N terminus of CTL epitopes ( Supplementary  Fig. 10b ). We analyzed all published ligands (1,620) of the most prevalent human HLA class I molecules in their flanking regions. Cumulatively, the results indicated that the dibasic cleavage motif of nardilysin 23, 24 was directly present at the N terminus or C terminus in 10.4% and 4.8% of the ligands, respectively. In another 5.2% and 5.7% of the 1,620 ligands, the motif was located within four amino acids of the N terminus or C terminus, respectively ( Table 2) . Thus, nardilysin can potentially liberate the precise N terminus or C terminus of many HLA class I ligands and may generate epitope precursors as well. The dibasic motif was most frequent directly at the N terminus of HLA-B27 ligands (35.2%) and at (basic) C termini of peptides presented by the HLA-A3 supertype (13%; Table 2 and Supplementary Table 1) .
We determined whether purified nardilysin actually excised prototypical ligands of HLA-A3 and HLA-B27 at the dibasic sites. The C termini of two overlapping immunodominant HLA-A3-restricted CTL epitopes from HIV type 1 (HIV-1) group-associated antigen (Gag p17) (ref. 29 ) and a naturally presented HLA-A11 ligand were Analysis of all ligands in the SYFPEITHI database for presence of the dibasic nardilysin motif, presented as the frequency (%) per HLA class I molecule. C-dir and N-dir, nardilysin motif at the C or N terminus, potentially leading to direct production of the C or N terminus, respectively; C-ind and N-ind, nardilysin motif within four amino acids flanking the C or N terminus, respectively, potentially leading to precursor formation. Far right, total frequency of ligands per allele potentially dependent on NRD cleavage for the generation of their N terminus or C terminus. 'Cumulative' indicates the frequency for HLA-A3, HLA-A11 and HLA-A68 (row 6) or HLA-B27 subtypes (row 18) or for all 1,620 ligands (bottom row).
efficiently produced (Fig. 4a) . Notably, 35.2% of all known HLA-B27 ligands contain a basic residue at position 1 (P1) next to their dominant HLA class I-binding arginine anchor at P2, which together constitute a dibasic motif ( Table 2 and Supplementary Table 1) . Nardilysin efficiently liberated the N terminus of eight prototypical HLA-B27 ligands (of eight ligands assessed) and in three cases also produced the C terminus at a dibasic site (Fig. 4b ). Among the peptides tested were immunodominant CTL epitopes from HIV-1 Gag p24 and Epstein-Barr virus protein EBNA3C 30 (Supplementary Table 2 ).
We assessed in more detail the N-terminal generation of the HLA-B2705-presented CTL epitope EBNA3C(258-266) (RRIYDLIEL) 30 . This epitope was excised efficiently from its N-terminal flanking region by nardilysin in a digestion of the 20-residue substrate EBNA3C(247-266) (Fig. 4b, bottom (Fig. 4c) .
The nardilysin dependence resided in the N-terminal processing, as shown by recognition of cells expressing an epitope precursor with extension of the N terminus (Fig. 4c) . Thus, although aminopeptidases exist in the cytosol and endoplasmic reticulum, nardilysin is required for excision of the EBNA epitope RRIYDLIEL.
TOP can do final C-terminal precursor trimming
It is believed that TOP destroys epitopes 6 , thereby limiting HLA class I antigen presentation 5 ; this raised the question of whether the excision of ELFSYLIEK by TOP is an exception. TOP preferentially releases, with broad sequence specificity 27, 31 , three to five C-terminal residues 25, 26 from substrates extending to up to 17 amino acids 27 , which endows TOP with the potential to generate the C terminus of epitopes. We assessed the flexibility of TOP in producing different epitope sequences by systematically substituting amino acids at the positions (P1 and P1′) surrounding the scissile bond after the C terminus of ELFSYLIEK (ELFSYLIE(P1-P1′)KRK). Substitutions at P1′ affected cleavage efficiency, but in all cases except proline at P1′, which prevented digestion, production of the epitope ELFSYLIEK was >5% after 10 min of Supplementary Fig. 5b) . Above, immunoblot analysis of nardilysin in RT cells transfected expressing control or nardilysin-specific siRNA. Data are from one experiment representative of four (s.e.m. of triplicate wells). 
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ELFSYLIEX VKRK (P1) Figure 5 The epitope-generating trimming capacity of TOP. (Fig. 5a) . Partial destruction by subsequent cleavage in the epitope occurred but did not prevent epitope production (Fig. 5a) , as also shown by efficient recognition of the digestion products by the anti-ELFSYLIEK CTL (Fig. 5b) . Digestion of the variants with substitution at P1 resulted in generation of the epitope ELFSYLIEX when the amino acid at P1 was lysine (wild-type sequence) or was arginine or glutamic acid (Fig. 5a) , but generation was inefficient or was absent when other amino acids were at this position. This was caused by inefficient cleavage after ELFSYLIEX for some amino acids at P1 (such as valine, isoleucine and aspartic acid) and/or by a rapid second cleavage in the middle of the epitope (such as phenylalanine, tryptophan, cysteine and tyrosine). The necessity for a lysine, arginine or glutamic acid at position P1 was not absolute, however. When we changed the epitope completely, TOP produced epitopes with a C-terminal alanine or leucine (SLYSFPEPEA and VLDGLDVLL) 20 (Table 3) . These results indicate that TOP, without distinct sequence specificity, can produce CTL epitopes from a wide array of precursors.
We searched for other TOP-dependent CTL epitopes by suppressing TOP in target cells via RNAi. We assessed the clinically important melanoma-specific and HLA-A2-restricted MART-1 epitope 32 , of which 9-residue and 10-residue variants (AAGIGILTV and EAAGIGILTV; amino acids 27-35 and 26-35, respectively) are considered to be naturally presented 33 , for recognition by CTLs and found that recognition of melanoma cells in which TOP was suppressed was much lower (Fig. 6a) , which indicates the dependence of presentation of the MART-1 epitope on TOP. We investigated the underlying mechanism by in vitro digestion of epitope precursors with extension of the C terminus. We did not find liberation of the epitope's C-terminal Val35, but purified TOP efficiently cleaved in these substrates after Leu33, Thr34 and Leu37; fragments containing those as the C terminus were each present as ≥6% of the total after 10 min of digestion (Fig. 6b) . Therefore, the requirement for TOP may be explained if the variant epitopes EAAGIGILT (MART-1(26-34) ) and/or AAGIGILTVIL (MART-1(27-37)) are among those naturally processed and recognized by CTLs. A CTL clone specific for MART-1(26-35) efficiently recognized those variant peptides when they were loaded exogenously (Fig. 6c) , although with lower sensitivity than its recognition of the peptide EAAGIGILTV (MART-1(26-35); Fig. 6d ).
Processing effects specific to HLA class I alleles In addition to producing HLA class I ligands, nardilysin and TOP will sometimes also destroy other (potential) HLA class I ligands. Consequently, depending on the balance between production and destruction, the absolute quantity of ligands available for loading onto HLA class I may be affected. Therefore, we measured cell surface expression of HLA class I under conditions of overexpression and suppression of these peptidases by RNAi. Consistent with published literature 5 , overexpression of TOP resulted in lower expression of HLA class I by HeLa cells (Supplementary Fig. 12a) . Likewise, overexpression of nardilysin led to modestly attenuated expression of HLA class I molecules overall by HeLa cells, and, specifically, of HLA-A3 and HLA-B27 by various cell types (Supplementary Fig. 12a,b) . These findings indicate that overexpression of both TOP and nardilysin, not unexpectedly, tilt the balance between the generation and destruction of HLA class I ligands by these peptidases. The contribution of each peptidase to the overall quantity of HLA class I ligands produced under physiological conditions is more likely to be identified by analysis of the abundance of HLA class I at the cell surface when peptidase expression is suppressed. We specifically focused on HLA-A2, HLA-A3 Liberation of the CTL epitopes (underlined) PRAME(142-151) (SLYSFPEPEA), PRAME(100-108) (VLDGLDVLL) and PRA (190) (191) (192) (193) (194) (195) (196) (197) (198) and HLA-B27 (naturally expressed by the B-lymphoblastoid cell lines HAR, RT and EKR), because these were the restriction elements of the epitopes identified in our experiments reported above and also because their ligands are presumed to be either dependent on the proteasome (HLA-A2) or relatively independent of the proteasome (HLA-A3 and HLA-B27) 11, 14, 15 . We observed effects specific for HLA class I alleles when nardilysin expression was suppressed. Cell surface expression of HLA-A2 and HLA-A3 was slightly enhanced (4-9%), which suggests a net destructive effect of nardilysin in the production of peptides presented by these HLA class I molecules, whereas expression of HLA-B27 and HLA-B35 was slightly lower (5-11%). The latter result suggests a net productive role for nardilysin in the generation of HLA-B27 and HLA-B35 ligands (Supplementary Fig. 12c ). When tested in the same B-lymphoblastoid cell lines, suppression of TOP led to a similar pattern of changes in the expression of HLA class I, consistently showing slightly lower expression of HLA-B27 and HLA-B35 and slightly enhanced expression of HLA-A2 and HLA-A3, whereas the expression of HLA-A24 and HLA-B7 was unaltered (Supplementary Fig. 12d ).
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Both the HAR and RT cells had the pattern of lower expression of HLA-B27 and enhanced expression of HLA-A2, which excluded the possibility of general nonspecific effects induced by RNAi. These alterations in the expression of HLA class I were not changed after incubation of the cells with brefeldin A to assess the possibility of differences in the off-rate of the peptides presented by cells in which these peptidases were suppressed versus control cells (data not shown), which indicated that nardilysin-or TOP-mediated processing does not alter the overall allele-specific HLA class I-peptide stability.
DISCUSSION
Here we have shown that the cytosolic endopeptidases nardilysin and TOP, either alone or together, were indispensable for the generation of three defined CTL epitopes. Nardilysin seemed to be involved in the generation of many HLA class I ligands either directly at or within four residues of their N or C terminus. In our digestions, nardilysin efficiently produced basic C termini (for binding to HLA-A3, HLA-A11 and HLA-B27), but it can also produce non-basic C termini for binding to other HLA class I molecules (Supplementary Fig. 10b ). The efficient cleavage of nardilysin at dibasic motifs suggests its application in the rational design of polyepitope vaccines through the insertion of dibasic moieties between CTL epitopes to guide epitope excision and enhance vaccine immunogenicity. A positive processing effect of a dibasic motif situated adjacent to a CTL epitope has been demonstrated before 34 . TOP efficiently liberated the epitope's C terminus in a variety of systematically substituted precursors of the ELFSYLIEK epitope and other epitopes, consistent with its known flexible ability in removing three to five C-terminal residues from the substrate [25] [26] [27] 31 . Purified TOP, however, did not liberate the anticipated C-terminal Val35 residue of the HLA-A2-restricted MART-1 epitope, of which two N-terminal variants (AAGIGILTV (amino acids [27] [28] [29] [30] [31] [32] [33] [34] [35] and EAAGIGILTV (amino acids [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] ) are considered to be naturally presented 33 . Instead, TOP cleaved after Leu33, Thr34 and Leu37. The peptide AEEAAGIGILT (MART-1 (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) ) is naturally presented by HLA-B45 (ref. 35) , which indicates endogenous liberation of Thr34 as a C terminus and suggests additional presentation of EAAGIGILT (MART-1 (26) (27) (28) (29) (30) (31) (32) (33) (34) ) by HLA-A2 as the explanation for the TOPdependent recognition by CTLs. Further experiments are needed to identify the natural presentation by HLA-A2 of a TOP-dependent variant peptide of MART-1.
A CTL epitope from the Mycobacterium tuberculosis protein Hsp65 with an undefined amino acid sequence has been shown to rely on TOP 36 . A possible role for TOP in the protection of some cytosolic peptides from further destruction has been documented 37 ; however, this has not been confirmed 38 . In contrast, results of biochemical studies and analysis of HLA class I expression 5, 6, 38, 39 have led to the idea that TOP has only a destructive role in HLA class I antigen processing 1, 2 . However, destruction of defined epitopes by TOP, as studied by CTL recognition of target cells with suppressed expression of TOP, has thus far been shown only for the mouse H2-K b -presented SIINFEKL epitope from ovalbumin 5 . The role of TOP in the production of the PRA (190) (191) (192) (193) (194) (195) (196) (197) (198) and MART-1 epitopes is in accordance with a study demonstrating that TOP in the cytosol both destroys and generates peptides of the length of HLA class I ligands 40 . Thus, the role of TOP in antigen processing seems to be twofold. TOP has a destructive role 5, 38 , limiting presentation of epitopes whose C terminus has already been made by, for example, the proteasome, such as SIINFEKL 5, 8 . However, TOP also generates C termini fit for binding by HLA class I via trimming of epitope precursors with extension of the C terminus. Thus, TOP-mediated processing both dampens the presentation of proteasomal products by HLA class I and enlarges the HLA class I peptide repertoire. This model fits both the literature and our results.
The proportion of HLA class I ligands that depend on nardilysin or TOP for their generation is not yet known. Our results have demonstrated HLA class I allele-specific influences of processing by nardilysin and TOP. Suppression of both peptidases slightly enhanced expression of HLA-A2 and HLA-A3, which indicated a destructive effect on ligand generation, as reported for TOP in the literature 5, 39 . Liberation of the aliphatic C terminus of HLA-A2 ligands is largely proteasome dependent. By trimming at the C terminus, TOP may destroy a substantial quantity of these HLA-A2 ligands. As for nardilysin, its dibasic cleavage motif was present at the C terminus (the C terminus itself and the residue at P1′) in 13% (31 of 238) of peptides presented by the HLA-A3 supertype. In our digestion studies, nardilysin produced two of these epitopes, but it may also destroy several of these peptides by cleaving in front of the dibasic motif, thereby diminishing the availability of HLA-A3 ligands. Notably, defined peptides that are presented by HLA class I molecules whose expression is quantitatively unaltered or enhanced after peptidase suppression may still depend on nardilysin or TOP. This is demonstrated by the finding that the PRA (190) (191) (192) (193) (194) (195) (196) (197) (198) and MART-1 epitopes, presented by HLA-A3 and HLA-A2, respectively, depended on nardilysin and/or TOP, which emphasizes the need for additional study of the processing of defined CTL epitopes.
However, suppression of nardilysin and TOP resulted in slightly lower expression of HLA-B27 and HLA-B35, which suggested a productive effect on ligand generation. Peptides presented by HLA-B27 (refs. 14,15) and HLA-B35 (ref. 11) have been found to be relatively insensitive to proteasome inhibition, consistent with the possibility of a role for cytosolic endopeptidases in their C-terminal generation. TOP can assist ligand formation for these HLA class I molecules by trimming precursors extended at the C terminus. As shown for the EBNA3 epitope and in the digestion studies, nardilysin can generate the N terminus of many HLA-B27 ligands by virtue of their frequent dibasic N-terminal moiety (35.2%) and can also liberate the C terminus of these ligands at a dibasic site. Thus nardilysin-mediated processing probably contributes to the substantial over-representation of arginine and lysine at P1 in HLA-B27 ligands, a position that contributes only modestly to binding. Another factor contributing to the prevalence of the N-terminal dibasic motif of HLA-B27 ligands may be that it enforces peptide stability in the cytosol 41 . Four of the eight HLA-B27 ligands that were excised by nardilysin at their N terminus have been found to be proteasome independent when studied with proteasome A r t i c l e s inhibitors 15 which supports the idea of a role for an additional peptidase in their generation. Most of the proteasome-inhibitor-insensitive HLA-B27 ligands in the previous study 15 were derived from small basic proteins, which also suggests that nardilysin is involved in their processing. However, all studies showing proteasome-independent peptide presentation by HLA class I through the use of proteasome inhibitors as the main experimental tool 11, 14, 15 should be evaluated with consideration of the residual proteasome activity still present in inhibitor-treated cells, which leaves unanswered the question of whether completely proteasome-independent CTL epitopes are ever produced in the cytosol. This is exemplified by the ELFSYLIEK epitope, which, although it was dependent on the proteasome for its N-terminal generation, nevertheless showed enhanced presentation after proteasome inhibition.
Because of their substrate length constraints of ~30 amino acids and ~17 amino acids, respectively, nardilysin and TOP probably act only after hydrolysis by the proteasome of either polypeptidic defective ribosomal products or full-length 'retired' proteins. The generation of the C terminus of the ELFSYLIEK epitope, which requires nardilysin cleavage before TOP can liberate the C terminus, again shows that both substrate length and amino acid sequence determine which peptidase acts where and at what time in cytosolic HLA class I antigen processing. With the addition of nardilysin and TOP to the list, four peptidases have now been identified in the C-terminal generation of CTL epitopes. TPPII has been shown to generate the HLA-A3-restricted Nef(73-82) epitope (amino acids 73-82 of the HIV protein negative factor) 16 . Beyond its established tripeptidyl aminopeptidase activity involved in the N-terminal generation of epitopes, a broad role for the endoproteolytic activity of TPPII in the C-terminal generation of epitopes has not yet been detected 18 . The HLA-A1-presented human tumor epitope from MAGE-A3 is reported to be produced by insulin-degrading enzyme 17 , but a general role for this peptidase in antigen processing remains to be established. Together, our results here and those published findings indicate that the idea that only the proteasome is responsible for the C-terminal generation of epitopes needs reappraisal. In conclusion, by producing HLA class I-binding peptides from protein-degradation fragments that are not yet fit for antigenic presentation, especially those that lack a HLA class I-binding C-terminal anchor, nardilysin and TOP broaden the diversity of the antigenic peptide repertoire. Thus, both peptidases expand the options for a successful CTL response to intracellular pathogens and cancer.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/natureimmunology/. 
